inactivated influenza vaccine + COVID-19 vaccine

This entry refers to a vaccination regimen involving the co-administration of a seasonal inactivated influenza vaccine (IIV) and a COVID-19 booster vaccine. This specific strategy is being evaluated by the McGill University Health Centre in a Phase II randomized controlled trial (NCT05911490) to optimize immunization protocols for people living with immunocompromising conditions (PLIC). The study compares the safety and immunogenicity of simultaneous co-administration against sequential administration (with a one-month interval) and investigates the effectiveness of subsequent COVID-19 boosters at 3-month versus 6-month intervals. The vaccines used are those recommended by the National Advisory Committee on Immunization (NACI) for moderate to severely immunocompromised patients.

Other names

inactivated influenza vaccine-McGill University Health Centre/Research Institute of the McGill University Health Centre-COVID-19-influenzaIIV + COVID-19 vaccineseasonal inactivated influenza vaccine + COVID-19 booster